Ligand Pharmaceuticals (LGND) Insider Trading & Ownership $101.60 +0.31 (+0.31%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$101.72 +0.12 (+0.12%) As of 05/23/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Ligand Pharmaceuticals (NASDAQ:LGND) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.90%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$1.40 MNumber OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$6.37 M Get LGND Insider Trade Alerts Want to know when executives and insiders are buying or selling Ligand Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address LGND Insider Buying and Selling by Quarter Ligand Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/9/2025Octavio EspinozaCFOBuy1,500$104.06$156,090.00 5/9/2025Todd C DavisCEOBuy9,510$105.20$1,000,452.00 3/4/2025Octavio EspinozaCFOSell5,000$115.03$575,150.00 12/23/2024Octavio EspinozaCFOSell2,104$116.37$244,842.48 11/27/2024John L LamattinaDirectorSell2,406$123.65$297,501.90 9/23/2024Andrew ReardonInsiderSell2,000$99.60$199,200.00 9/23/2024Matthew E KorenbergCOOSell9,772$101.22$989,121.84 9/20/2024Matthew E KorenbergCOOSell6,275$104.10$653,227.50 9/20/2024Octavio EspinozaCFOSell1,275$103.94$132,523.50 8/28/2024Andrew ReardonInsiderSell1,500$106.39$159,585.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/26/2024Matthew E KorenbergCOOSell11,389$105.61$1,202,792.29 8/22/2024Matthew E KorenbergCOOSell1,157$105.54$122,109.78 8/9/2024Matthew E KorenbergCOOSell18,245$98.50$1,797,132.50 8/8/2024Todd C DavisCEOBuy2,500$97.39$243,475.00 (Data available from 1/1/2013 forward) LGND Insider Trading Activity - Frequently Asked Questions Who is on Ligand Pharmaceuticals's Insider Roster? The list of insiders at Ligand Pharmaceuticals includes Andrew Reardon, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Nancy Ryan Gray, Octavio Espinoza, Stephen L Sabba, and Todd C Davis. Learn more on insiders at LGND. What percentage of Ligand Pharmaceuticals stock is owned by insiders? 5.90% of Ligand Pharmaceuticals stock is owned by insiders. Learn more on LGND's insider holdings. Which Ligand Pharmaceuticals insiders have been buying company stock? The following insiders have purchased LGND shares in the last 24 months: Octavio Espinoza ($156,090.00), and Todd C Davis ($1,481,447.00). How much insider buying is happening at Ligand Pharmaceuticals? Insiders have purchased a total of 17,510 LGND shares in the last 24 months for a total of $1,637,537.00 bought. Which Ligand Pharmaceuticals insiders have been selling company stock? The following insiders have sold LGND shares in the last 24 months: Andrew Reardon ($1,189,185.00), John L Lamattina ($297,501.90), Matthew E Korenberg ($5,055,201.51), Nancy Ryan Gray ($77,708.80), Octavio Espinoza ($1,916,856.07), and Stephen L Sabba ($140,649.90). How much insider selling is happening at Ligand Pharmaceuticals? Insiders have sold a total of 88,559 Ligand Pharmaceuticals shares in the last 24 months for a total of $8,677,103.18 sold. Ligand Pharmaceuticals Key ExecutivesMr. Matthew E. Korenberg (Age 49)President & COO Compensation: $831.77kMr. Octavio Espinoza (Age 53)Chief Financial Officer Compensation: $613.59k3 recent tradesMr. Andrew T. Reardon J.D. (Age 49)Chief Legal Officer & Secretary Compensation: $614.87kMr. Scott M. Plesha (Age 59)Chief Executive Officer Mr. Paul J. HaddenSenior Vice President of Investments & Business DevelopmentSimon LatimerHead of Investor RelationsMr. Todd PettingillDirector of Corporate DevelopmentMs. Audrey Warfield-GrahamChief People OfficerDr. Keith MarschkeSenior Vice President of Biology & Scientific AffairsDr. Vincent D. Antle (Age 55)Senior Vice President of Technical Operations & QA - Capitsol More Insider Trading Tools from MarketBeat Related Companies RGEN Insider Trading HALO Insider Trading MDGL Insider Trading IONS Insider Trading ALKS Insider Trading BCRX Insider Trading FOLD Insider Trading CLDX Insider Trading MNKD Insider Trading NVAX Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Turbulence for Joby Shares: What's Behind the Recent Dip?UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Sprouts Stock: Insider Sales, But Strong Bullish Signals5 Hot Small-Cap Insiders Bought at the Peak of Tariff FearsThe Top-Ranked Insider Buys From April by Market Cap This page (NASDAQ:LGND) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LGND Stock Free LGND Stock Alerts